N-(2-(2-(4-クロロフェニル)チアゾール-4-イル)エチル)ブチルアミド
|
- ¥22500 - ¥1714500
- 化學名: N-(2-(2-(4-クロロフェニル)チアゾール-4-イル)エチル)ブチルアミド
- 英語名: N-(2-(2-(4-chlorophenyl)thiazol-4-yl)ethyl)butyraMide
- 別名:N-(2-(2-(4-クロロフェニル)チアゾール-4-イル)エチル)ブチルアミド
- CAS番號: 932986-18-0
- 分子式: C15H17ClN2OS
- 分子量: 308.83
- EINECS:
- MDL Number:MFCD08009374
6物価
選択條件:
ブランド
- 富士フイルム和光純薬株式會社(wako)
パッケージ
- 100mg
- 250mg
- 1g
- 5g
- 生産者富士フイルム和光純薬株式會社(wako)
- 製品番號W01COBQM-9695
- 製品説明N-(2-(2-(4-クロロフェニル)チアゾール-4-イル)エチル)ブチルアミド
- 英語製品説明N-(2-(2-(4-Chlorophenyl)thiazol-4-yl)ethyl)butyramide
- 包裝単位100mg
- 価格¥22500
- 更新しました2024-03-01
- 購入
- 生産者富士フイルム和光純薬株式會社(wako)
- 製品番號W01COBQM-9695
- 製品説明N-(2-(2-(4-クロロフェニル)チアゾール-4-イル)エチル)ブチルアミド
- 英語製品説明N-(2-(2-(4-Chlorophenyl)thiazol-4-yl)ethyl)butyramide
- 包裝単位250mg
- 価格¥39000
- 更新しました2024-03-01
- 購入
- 生産者富士フイルム和光純薬株式會社(wako)
- 製品番號W01COBQM-9695
- 製品説明N-(2-(2-(4-クロロフェニル)チアゾール-4-イル)エチル)ブチルアミド
- 英語製品説明N-(2-(2-(4-Chlorophenyl)thiazol-4-yl)ethyl)butyramide
- 包裝単位1g
- 価格¥105000
- 更新しました2024-03-01
- 購入
- 生産者富士フイルム和光純薬株式會社(wako)
- 製品番號W01FLC307025
- 製品説明N-(2-(2-(4-クロロフェニル)チアゾール-4-イル)エチル)ブチルアミド
- 英語製品説明N-(2-(2-(4-Chlorophenyl)thiazol-4-yl)ethyl)butyramide
- 包裝単位250mg
- 価格¥111300
- 更新しました2021-03-23
- 購入
- 生産者富士フイルム和光純薬株式會社(wako)
- 製品番號W01FLC307025
- 製品説明
- 英語製品説明N-(2-(2-(4-Chlorophenyl)thiazol-4-yl)ethyl)butyramide
- 包裝単位1g
- 価格¥280000
- 更新しました2021-03-23
- 購入
- 生産者富士フイルム和光純薬株式會社(wako)
- 製品番號W01COBQM-9695
- 製品説明N-(2-(2-(4-クロロフェニル)チアゾール-4-イル)エチル)ブチルアミド
- 英語製品説明N-(2-(2-(4-Chlorophenyl)thiazol-4-yl)ethyl)butyramide
- 包裝単位5g
- 価格¥1714500
- 更新しました2023-06-01
- 購入
| 生産者 | 製品番號 | 製品説明 | 包裝単位 | 価格 | 更新時間 | 購入 |
|---|---|---|---|---|---|---|
| 富士フイルム和光純薬株式會社(wako) | W01COBQM-9695 | N-(2-(2-(4-クロロフェニル)チアゾール-4-イル)エチル)ブチルアミド N-(2-(2-(4-Chlorophenyl)thiazol-4-yl)ethyl)butyramide |
100mg | ¥22500 | 2024-03-01 | 購入 |
| 富士フイルム和光純薬株式會社(wako) | W01COBQM-9695 | N-(2-(2-(4-クロロフェニル)チアゾール-4-イル)エチル)ブチルアミド N-(2-(2-(4-Chlorophenyl)thiazol-4-yl)ethyl)butyramide |
250mg | ¥39000 | 2024-03-01 | 購入 |
| 富士フイルム和光純薬株式會社(wako) | W01COBQM-9695 | N-(2-(2-(4-クロロフェニル)チアゾール-4-イル)エチル)ブチルアミド N-(2-(2-(4-Chlorophenyl)thiazol-4-yl)ethyl)butyramide |
1g | ¥105000 | 2024-03-01 | 購入 |
| 富士フイルム和光純薬株式會社(wako) | W01FLC307025 | N-(2-(2-(4-クロロフェニル)チアゾール-4-イル)エチル)ブチルアミド N-(2-(2-(4-Chlorophenyl)thiazol-4-yl)ethyl)butyramide |
250mg | ¥111300 | 2021-03-23 | 購入 |
| 富士フイルム和光純薬株式會社(wako) | W01FLC307025 | N-(2-(2-(4-Chlorophenyl)thiazol-4-yl)ethyl)butyramide |
1g | ¥280000 | 2021-03-23 | 購入 |
| 富士フイルム和光純薬株式會社(wako) | W01COBQM-9695 | N-(2-(2-(4-クロロフェニル)チアゾール-4-イル)エチル)ブチルアミド N-(2-(2-(4-Chlorophenyl)thiazol-4-yl)ethyl)butyramide |
5g | ¥1714500 | 2023-06-01 | 購入 |
プロパティ
融點 :90-93°C
比重(密度) :1.215
貯蔵溫度 :-20°C
溶解性 :Soluble in DMSO (up to at least 25 mg/ml) or in ethanol (up to at least 25 mg/ml)
外見 :solid
色 :Off-white
安定性: :Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
InChI :1S/C15H17ClN2OS/c1-2-3-14(19)17-9-8-13-10-20-15(18-13)11-4-6-12(16)7-5-11/h4-7,10H,2-3,8-9H2,1H3,(H,17,19)
InChIKey :VYBFWKKCWTXCQX-UHFFFAOYSA-N
SMILES :ClC1=CC=C(C2=NC(CCNC(CCC)=O)=CS2)C=C1
比重(密度) :1.215
貯蔵溫度 :-20°C
溶解性 :Soluble in DMSO (up to at least 25 mg/ml) or in ethanol (up to at least 25 mg/ml)
外見 :solid
色 :Off-white
安定性: :Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
InChI :1S/C15H17ClN2OS/c1-2-3-14(19)17-9-8-13-10-20-15(18-13)11-4-6-12(16)7-5-11/h4-7,10H,2-3,8-9H2,1H3,(H,17,19)
InChIKey :VYBFWKKCWTXCQX-UHFFFAOYSA-N
SMILES :ClC1=CC=C(C2=NC(CCNC(CCC)=O)=CS2)C=C1
安全情報
| 絵表示(GHS): |
|
||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 注意喚起語: | Warning | ||||||||||||||||||||||||||||
| 危険有害性情報: |
|
||||||||||||||||||||||||||||
| 注意書き: |
|
説明
The unfolded protein response (UPR) maintains balance between protein synthesis and endoplasmic reticulum (ER) protein-folding by inhibiting translation to decrease global protein synthesis, increasing degradation and disposal of unfolded protein intermediates from the ER, and increasing the folding capacity of the ER by expanding its volume and increasing chaperone synthesis. Chronic ER stress leads to a defective UPR and is strongly associated with neurodegenerative diseases, cancers, and metabolic syndrome. Azoramide is a small molecule that has been shown to improve ER protein-folding ability by dose-dependently (1-25 μM) activating reporter genes whose expression is driven by the cellular UPR response element and the ER stress response element. At 1-25 μM, this compound can also stimulate the expression of multiple chaperone proteins to enhance ER chaperone capacity and induce phosphorylation of eukaryotic translation initiation factor 2α subunit (eIF2α) to reduce protein synthesis. At 150 mg/kg, azoramide exerts antidiabetic activity in both ob/ob and diet-induced obese mice, improving insulin sensitivity and glucose homeostasis, as well as protecting pancreatic β cells against ER stress.関連商品価格
- アゾイックジアゾコンポーネント22
¥1600-50710 - ホルムアニリド
¥3740-39900 - アセチルファルネシルシステイン
¥9000-442500



